Introduction: Navigating the Psychedelic Frontier
In recent years, the scientific community has turned its attention toward the potential benefits of microdosing psilocybin – a practice that involves consuming small, sub-perceptual amounts of the psychedelic compound found in magic mushrooms. Today, we look at what a major study from Imperial College London found when it put psychedelic microdosing to a placebo-controlled test.
Chapter 1: Setting the Stage – The Rise of Psychedelic Research in the UK
1.1 The Renewed Interest in Psychedelics
Interest in psychedelic research has grown in recent years, and Imperial College London has been one of the leading centres, with studies on substances including psilocybin.
Chapter 2: Unpacking the Microdosing Phenomenon
2.1 Defining Microdosing
Microdosing is the practice of regularly taking very small amounts of a psychedelic drug. People who microdose often say it improves their well-being and thinking, but reports like these can be skewed by the placebo effect.
2.2 The UK Microdosing Study
The Imperial College London study was published in the journal eLife in March 2021 (Szigeti et al.). It used a ‘self-blinding’ design: 191 people who had already chosen to microdose took part alongside look-alike placebos, so they did not know which they were taking in a given week. The researchers did not supply or test the substances used. Most participants microdosed with LSD or a similar compound; about a quarter used psilocybin mushrooms.
Chapter 3: Key Findings – A Glimpse into the Microdosing Realm
3.1 How the Microdose and Placebo Groups Compared
Well-being and other psychological measures improved over four weeks in the microdose group, but the placebo group improved too, and there was no significant difference between the two. Short-term differences in mood, energy and creativity disappeared once researchers accounted for whether participants had guessed what they were taking, and cognitive test scores did not differ between groups. The authors concluded that the reported benefits of microdosing can be explained by the placebo effect.
Chapter 4: Potential Applications and Future Directions
4.1 Therapeutic Applications
The Imperial study does not support using microdosing as a treatment for depression, anxiety or any other condition.
4.2 Future Research and Implications
The Imperial study left open questions, including what microdosing does over the longer term, and other research teams have since run their own placebo-controlled tests.
Later placebo-controlled studies have reported similar results. A double-blind study in Argentina found no effect on creativity or cognition compared with placebo (Cavanna et al., 2022), and two trials from Leiden University found no significant effects after statistical correction, including on self-reported cognitive flexibility (Prochazkova et al., 2026). Not all researchers agree: a 2024 review of 19 placebo-controlled studies found some measurable differences from placebo and concluded it is ‘not yet possible to determine whether microdosing is a placebo’ (Polito & Liknaitzky). A 2026 systematic review rated the overall certainty of the evidence as low (Page et al.).
Observational studies such as Rootman et al. 2022 report mood improvements; placebo-controlled trials have not confirmed them.
Conclusion: Nurturing a Psychedelic Renaissance in the UK
As we conclude our look at Imperial College London’s research on microdosing, it becomes evident that the psychedelic renaissance is in full swing. The study’s main contribution is a careful test: its results suggest that most of the benefits people report from microdosing can be explained by expectation, and later research has not yet settled the question.
Imperial College London’s work remains a useful model for how psychedelic research should be done, showing why placebo controls matter when testing claims about microdosing. That kind of rigour is what the psychedelic renaissance depends on, and we will keep reporting on new findings as they are published.
This blog post is for informational purposes only and does not constitute medical advice.
Sources
- Imperial College London – Centre for Interventional Psychiatry and Psychedelic Research. https://www.imperial.ac.uk/psychedelic-research-centre/
- Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D. Self-blinding citizen science to explore psychedelic microdosing. eLife, 2021. https://elifesciences.org/articles/62878
- Cavanna F, et al. Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. Translational Psychiatry, 2022. https://www.nature.com/articles/s41398-022-02039-0
- Prochazkova L, et al. Cognitive and subjective effects of psilocybin microdosing: results from two double-blind placebo-controlled longitudinal trials. Neuropharmacology, 2026. https://pubmed.ncbi.nlm.nih.gov/41110634/
- Polito V, Liknaitzky P. Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. Journal of Psychopharmacology, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311906
- Page J, et al. The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing. Frontiers in Psychiatry, 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13533901/
- Rootman JM, et al. Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls. Scientific Reports, 2022. https://www.nature.com/articles/s41598-022-14512-3
